C.-M. Lee

527 SUSTAINED HCV CLEARANCE AND INCREASED HBSAG SEROCLEARANCE IN PATIENTS WITH DUAL CHRONIC HEPATITIS C AND B POST-PEGINTERFERON ALFA-2A AND RIBAVIRIN TREATMENT: A 5-YEAR FOLLOW-UP

8 weeks than that of in placebo group, but there were no significant difference between lamivudine and entecavir group. The number of patients in lamivudine and entecavir group with undetectable HBV DNA was 30.5% and 36.6% at week 12 respectively, there was significant difference between two groups (P < 0.05). Among patients with HBeAg positive diseases, 45.3% patients in lamivudine group and 44.7% in entecavir group lost HBeAg at follow up week 12 respectively, whereas none in placebo group. 36.0% patients in lamivudine group and 34.2% in entecavir group had HBeAg seroconversion at week 12, while none of patient in placebo had HBeAg seroconversion at follow up period. Conclusion: Antiviral treatment therapy can significantly reduce the mortality of patients with chronic hepatitis B liver failure. Both lamivudine and entecavir can be prescribed as an initial treatment in patients with chronic hepatitis B liver failure to reduce the mortality.

697 AN OPEN-LABEL, COMPARATIVE, MULTICENTRE STUDY OF PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN IN THE TREATMENT OF PATIENTS CHRONICALLY INFECTED WITH HCV/HBV OR HCV ALONE

C.-J. Liu1, W.-L. Chuang2, C.-M. Lee3, S.-S. Wu4, L.-Y. Liao5, H.-T. Kuo6, Y.-C. Chao7, C.-L. Chen1, P.-J. Chen1, D.-S. Chen1. 1National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, 2Kaohsiung Medical University Hospital, Kaohsiung, 3Chang Gung Memorial Hospital, Kaohsiung, 4Changhua Christian Hospital, Changhua, 5Ren-Ai Branch, Taipei City Hospital, Taipei, 6Chi-Mei Medical Center, Tainan, 7Tri-Service General Hospital, Taipei, Taiwan E-mail: karensearle@elementscommunications.com